Effect of phosphodiesterase inhibitors in the bladder

Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients. PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, K-channel modulated pathways, and the l-cystei...

Descripción completa

Detalles Bibliográficos
Autores principales: Chughtai, Bilal, Ali, Aizaz, Dunphy, Claire, Kaplan, Steven A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730687/
https://www.ncbi.nlm.nih.gov/pubmed/29264117
http://dx.doi.org/10.1016/j.ajur.2015.04.014
Descripción
Sumario:Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients. PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, K-channel modulated pathways, and the l-cysteine/H(2)S pathway. PDE5 inhibitors exert their effect in muscle cells, nerve fibers, and interstitial cells (ICs). The use of PDE5 inhibitors led to improvement in LUTS. This included urodynamic parameters. PDE5 inhibitors may play a significant role in LUTS due to their effect on the bladder rather than the prostate.

Ejemplares similares